21 March 2025
We are excited to announce the release of our latest Environmental, Social, and Governance (ESG) report. This detailed document showcases our significant achievements from November 2023 to October 2024, as well as describing all our ESG activities and processes.
Yesterday, Oxford PharmaGenesis really went the extra mile to raise money for Sport Relief. Our keen trotters ran a total of 32.5 miles over courses in Tubney, Oxfordshire, Trafalgar Square, London, and Newtown, PA, USA, and raised more than £300.
Multiple aspects of HealthScience – including rare diseases, real-world evidence, and health economics and outcomes research – were major topics for discussion at the 15th Annual Meeting of The International Publication Planning Association (TIPPA) last week, sponsored by Oxford PharmaGenesis. The meeting, held in San Diego on 29 February–1 March 2016, was attended by a…
Our research demonstrating the value of professional medical writing support has gained remarkable online attention since publication last week in BMJ Open. Based on a combination of online attention and sharing on social media, our article has achieved an Altmetric score of 52, putting it in the top 5% of all research outputs scored by…
Oxford PharmaGenesis this week expanded its real-world evidence experience into the areas of respiratory and infectious diseases, with the commissioning of two new SURE™ (Systematic Understanding of Real-World Evidence) assessments. This brings to double digits the number of SURE™ projects initiated in the past 12 months, which have covered cardiology, neurology, diabetes, endocrinology, oncology, immunology…
Professional medical writing support improves the quality of clinical trial reporting, according to a new study conducted by Oxford PharmaGenesis and published in BMJ Open today. The research shows that compliance with reporting guidelines in medical journal articles almost doubles when medical writers are involved. The quality of written English is also significantly improved with…
“If you imagine the symptoms of Alzheimer’s disease, Parkinson’s disease, motor neurone disease and epilepsy all rolled in to one, it gives you a good idea of how a child with neuronal ceroid lipofuscinosis (NCL) is affected,” says Kim Wager, Associate Consultant at Oxford PharmaGenesis. “Currently, there are no effective therapies, so obtaining research funding…
